LYNBROOK, N.Y., Nov. 20 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (BULLETIN BOARD: BSTC) , a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Thomas Wegman, will present at the upcoming Piper Jaffray 20th Annual Health Care Conference on Tuesday, December 2, 2008, at 4:30pm ET at the New York Palace Hotel in New York, NY.
A live webcast of the presentation can be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BSTC&item_id=2021200.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis). It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. Positive top line results from the Phase III clinical trials with XIAFLEX(TM) for treatment of Dupuytren's disease were released in June 2008. More information about the company may be found on its website at http://www.biospecifics.com/.
